New scan could spot Hard-to-Find breast cancer spread

NCT ID NCT07020806

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new radioactive tracer called [68Ga]Ga DOTA-5G for PET/CT scans in 30 people with metastatic lobular breast cancer. The goal is to see if it can find cancer lesions better than current methods and to check its safety. Participants receive one injection and are scanned at 1 and 2 hours after.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

[68Ga]Ga DOTA-5G (a radioactive tracer for PET imaging)

What this could lead to

If successful, this could provide a more accurate way to detect metastatic lobular breast cancer, helping doctors plan better treatment.

What could go wrong

This is a very early Phase 1 trial with only 30 people. The imaging agent may not prove more effective than current scans, and safety is still being checked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LOBULAR BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Lobular invasive lobular breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis

    RECRUITING

    Sacramento, California, 95817, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact